Therapeuticsmd Inc Up 2.51% To $4.50 After Earnings Miss

Therapeuticsmd Inc (TXMD) said after close Monday that it lost $0.24 per share in quarter one 2023.

On the revenue line, the company reported $416 thousand, missing estimates by $1.3 million.

In the same quarter a year ago, the company lost $4.72 per share on revenue of $19.3 million.

The stock is up 2.51% to $4.50 after the report.

The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.

Wall Street Analysts had an average rating of Hold on the stock prior to the report.

Trading in the five days leading up to the report earned Therapeuticsmd Inc a Bullish Sentiment Rank from InvestorsObserver.

Therapeuticsmd Inc has performed a little above average during the past few months. Before the report, Therapeuticsmd Inc received a Long-Term Technical Rank by InvestorsObserver of 50, putting it in the top half of stocks. The firm set a 52-week high on August 15, 2022 at $11.69 and set a 52-week low on May 26, 2022 at $1.99.

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.